Literature DB >> 7903074

Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation.

F A Vyth-Dreese1, T A Dellemijn, A Frijhoff, Y van Kooyk, C G Figdor.   

Abstract

Major adhesion routes between lymphoid cells involve the receptor/ligand pairs LFA-1/ICAM-1 and CD2/LFA-3, in addition to VLA or CD44 molecules. In this study we evaluated the role of these adhesion receptors in the proliferative response of lymphoid cells to interleukin-2 (IL-2). Blocking studies were performed with a panel of monoclonal antibodies (mAb) directed against these adhesion molecules. Selective inhibition of recombinant (r)IL-2-induced cell proliferation was observed with mAb directed against the alpha or beta subunit of LFA-1 or to its ligand ICAM-1. Interestingly, rIL-2-induced proliferation was also inhibited by NKI-L16, and anti-1 alpha antibody known to enhance cell-cell interaction. Resting lymphocytes were preferentially susceptible to the inhibition, particularly in an early phase of culture and when stimulated with a relatively low dose of rIL-2. By using mAb that specifically could block distinct rIL-2 activation pathways, LFA-1/ICAM-1 interaction was found to be required for p55 IL-2 receptor (IL-2R)-mediated interaction of rIL-2 with its high-affinity receptor, but not for p75 IL-2R-mediated responses. Furthermore, it was shown that the rIL-2 response of T lymphocytes, but not of natural killer cells, was dependent on LFA-1/ICAM-1 interaction. This suggests that LFA-1/ICAM-1 interaction is required for an optimal rIL-2 response of cells capable of IL-2 secretion. Our data provide evidence for the hypothesis that adhesion receptor-directed release of IL-2 may result in a locally high concentration of IL-2 that triggers high-affinity IL-2R signaling and up-regulates p55 IL-2R to enhance cytokine responsiveness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903074     DOI: 10.1002/eji.1830231235

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  The immune system in the elderly: III. Innate immunity.

Authors:  L Ginaldi; M De Martinis; A D'Ostilio; L Marini; M F Loreto; D Quaglino
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Functions of γC cytokines in immune homeostasis: current and potential clinical applications.

Authors:  Willem W Overwijk; Kimberly S Schluns
Journal:  Clin Immunol       Date:  2009-05-09       Impact factor: 3.969

3.  T-cell-mediated immunity to lymphocytic choriomeningitis virus in beta2-integrin (CD18)- and ICAM-1 (CD54)-deficient mice.

Authors:  J P Christensen; O Marker; A R Thomsen
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

4.  Parametrial fat tissue from high fat diet-treated SKH-1 mice stimulates transformation of mouse epidermal JB6 cells.

Authors:  Jamie J Bernard; You-Rong Lou; Qing-Yun Peng; Tao Li; Priyal R Vakil; Ning Ding; Jeffrey D Laskin; Zigang Dong; Allan H Conney; Yao-Ping Lu
Journal:  J Carcinog Mutagen       Date:  2014-07-31

5.  LFA-1 subunit expression in ulcerative colitis patients.

Authors:  I Kirman; O H Nielsen
Journal:  Dig Dis Sci       Date:  1996-04       Impact factor: 3.199

6.  Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity.

Authors:  Pingtao Tang; Tammy P Cheng; Davide Agnello; Chang-You Wu; Bruce D Hissong; Wendy T Watford; Hyun-Jong Ahn; Jerome Galon; Joel Moss; Martha Vaughan; John J O'Shea; Massimo Gadina
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 7.  Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.

Authors:  A Kinter; A S Fauci
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

8.  Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells.

Authors:  M Böhm; P Möller; U Kalbfleisch; M Worm; B M Czarnetzki; D Schadendorf
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.